Crossject (PA:ALCJ) — Market Cap & Net Worth
Market Cap & Net Worth: Crossject (ALCJ)
Crossject (PA:ALCJ) has a market capitalization of $94.25 Million (€80.62 Million) as of August 4, 2026. Listed on the PA stock exchange, this France-based company holds position #19356 globally and #292 in its home market, demonstrating a 0.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crossject's stock price €1.51 by its total outstanding shares 53246686 (53.25 Million). Review ALCJ total liabilities to assess the company's total debt and financial obligations.
Crossject Market Cap History: 2015 to 2026
Crossject's market capitalization history from 2015 to 2026. Data shows change from $609.37 Million to $94.25 Million (-8.29% CAGR).
Index Memberships
Crossject is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$39.47 Billion | 0.24% | #20 of 34 |
Weight: Crossject's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Crossject Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crossject's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.58x
Crossject's market cap is 33.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $266.34 Million | $1.42 Million | -$6.66 Million | 187.21x | N/A |
| 2017 | $275.09 Million | $3.23 Million | -$7.61 Million | 85.05x | N/A |
| 2018 | $73.99 Million | $2.44 Million | -$10.71 Million | 30.27x | N/A |
| 2019 | $141.12 Million | $500.00K | -$7.17 Million | 282.23x | N/A |
| 2020 | $188.05 Million | $4.84 Million | -$9.84 Million | 38.82x | N/A |
| 2021 | $174.86 Million | $912.00K | -$10.81 Million | 191.74x | N/A |
| 2022 | $203.33 Million | $954.00K | -$11.16 Million | 213.13x | N/A |
| 2023 | $306.69 Million | $145.00K | -$8.64 Million | 2115.07x | N/A |
| 2024 | $138.20 Million | $4.12 Million | -$12.79 Million | 33.58x | N/A |
Competitor Companies of ALCJ by Market Capitalization
Companies near Crossject in the global market cap rankings as of August 4, 2026.
Key companies related to Crossject by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #174 globally with a market cap of $132.96 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #283 globally with a market cap of $91.81 Billion USD ( €78.53 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #345 globally with a market cap of $78.07 Billion USD ( €66.78 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #532 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #174 | Intuitive Surgical Inc | NASDAQ:ISRG | $132.96 Billion | $375.41 |
| #283 | EssilorLuxottica S. A. | PA:EL | $91.81 Billion | €169.60 |
| #345 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $78.07 Billion | €81.00 |
| #532 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Crossject Historical Marketcap From 2015 to 2026
Between 2015 and today, Crossject's market cap moved from $609.37 Million to $ 94.25 Million, with a yearly change of -8.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €94.25 Million | -30.87% |
| 2025 | €136.33 Million | -1.35% |
| 2024 | €138.20 Million | -54.94% |
| 2023 | €306.69 Million | +50.83% |
| 2022 | €203.33 Million | +16.28% |
| 2021 | €174.86 Million | -7.01% |
| 2020 | €188.05 Million | +33.26% |
| 2019 | €141.12 Million | +90.72% |
| 2018 | €73.99 Million | -73.10% |
| 2017 | €275.09 Million | +3.28% |
| 2016 | €266.34 Million | -56.29% |
| 2015 | €609.37 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Crossject was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $94.25 Million USD |
| MoneyControl | $94.25 Million USD |
| MarketWatch | $94.25 Million USD |
| marketcap.company | $94.25 Million USD |
| Reuters | $94.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more